BriaPro Therapeutics reports $299,950 in cash for interim period.

BriaPro Therapeutics Corp. filed unaudited interim financial statements for the period ended April 30, 2026, showing a substantial increase in total assets. The filing highlights a significant improvement in liquidity to approximately $300,000 in cash and cash equivalents, contrasting with the minimal balance reported in the prior year.